About: Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $12.15 (+0.66%)
ARCT NASDAQ Arcturus Therapeutics Holdings Inc
Arcturus Therapeutics Holdings Inc share price
Atividade de preço de ARCT
Último preço
$ 12,150
Variação (24h)
0,08 USD (0,66%)
Volume
472.44K
Volume (média 4 sem.)
-
Abertura
$ 12,07
Variação do dia
$ 11,94 - $ 12,44
Fechamento anterior
$ 12,07
Último negócio
29 Oct, 8:00 pm GMT+0
Atrasado
29 Oct, 8:00 pm GMT+0
ARCT price performance
Atrasado
29 Oct, 8:00 pm GMT+0
quote.marketSignals